Pfizer Says Phase 3 Elrexfio Study Meets Primary Endpoint
Pfizer said its phase 3 MagnetisMM-32 study of Elrexfio in relapsed or refractory multiple myeloma met its primary endpoint.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pfizer Says ELREXFIO Meets Primary Endpoint in Phase 3 Study
Pfizer announced topline results from the Phase 3 MagnetisMM-32 study of ELREXFIO in adults with relapsed or refractory multiple myeloma.